Frontera Therapeutics is a global, clinical-stage biotech company creating advanced AAV (adeno-associated virus) gene therapies for rare and common diseases, using their proprietary APEX platform for better vectors and a Suzhou GMP facility for low-cost, high-quality production.
​China-based biotech company Frontera aims to raise $100 million through Hong Kong listing. We look at its core products FT-003 and FT-002, pre-IPO...